En español
NIDA

Common Comorbidities with Substance Use Disorders

References

  1. Santucci K. Psychiatric disease and drug abuse. Curr Opin Pediatr. 2012;24(2):233-237. doi:10.1097/MOP.0b013e3283504fbf.
  2. Ross S, Peselow E. Co-occurring psychotic and addictive disorders: neurobiology and diagnosis. Clin Neuropharmacol. 2012;35(5):235-243. doi:10.1097/WNF.0b013e318261e193.
  3. Kelly TM, Daley DC. Integrated Treatment of Substance Use and Psychiatric Disorders. Soc Work Public Health. 2013;28(0):388-406. doi:10.1080/19371918.2013.774673.
  4. Hser YI, Grella CE, Hubbard RL, et al. An evaluation of drug treatments for adolescents in 4 US cities. Arch Gen Psychiatry. 2001;58(7):689-695.
  5. Magidson JF, Liu S-M, Lejuez CW, Blanco C. Comparison of the Course of Substance Use Disorders among Individuals With and Without Generalized Anxiety Disorder in a Nationally Representative Sample. J Psychiatr Res. 2012;46(5):659-666. doi:10.1016/j.jpsychires.2012.02.011.
  6. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67(2):247-257.
  7. Brady KT, Haynes LF, Hartwell KJ, Killeen TK. Substance use disorders and anxiety: a treatment challenge for social workers. Soc Work Public Health. 2013;28(3-4):407-423. doi:10.1080/19371918.2013.774675.
  8. Wolitzky-Taylor K, Operskalski JT, Ries R, Craske MG, Roy-Byrne P. Understanding and treating comorbid anxiety disorders in substance users: review and future directions. J Addict Med. 2011;5(4):233-247. doi:10.1097/ADM.0b013e31823276d7.
  9. Torrens M, Gilchrist G, Domingo-Salvany A, psyCoBarcelona Group. Psychiatric comorbidity in illicit drug users: substance-induced versus independent disorders. Drug Alcohol Depend. 2011;113(2-3):147-156. doi:10.1016/j.drugalcdep.2010.07.013.
  10. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64(5):566-576. doi:10.1001/archpsyc.64.5.566.
  11. Pettinati HM, O’Brien CP, Dundon WD. Current Status of Co-Occurring Mood and Substance Use Disorders: A New Therapeutic Target. Am J Psychiatry. 2013;170(1):23-30. doi:10.1176/appi.ajp.2012.12010112.
  12. De Alwis D, Lynskey MT, Reiersen AM, Agrawal A. Attention-deficit/hyperactivity disorder subtypes and substance use and use disorders in NESARC. Addict Behav. 2014;39(8):1278-1285. doi:10.1016/j.addbeh.2014.04.003.
  13. Harstad E, Levy S, Abuse C on S. Attention-Deficit/Hyperactivity Disorder and Substance Abuse. Pediatrics. 2014;134(1):e293-e301. doi:10.1542/peds.2014-0992.
  14. Hartz SM, Pato CN, Medeiros H, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry. 2014;71(3):248-254. doi:10.1001/jamapsychiatry.2013.3726.
  15. Flórez-Salamanca L, Secades-Villa R, Budney AJ, García-Rodríguez O, Wang S, Blanco C. Probability and predictors of cannabis use disorders relapse: Results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2013;132(0):127-133. doi:10.1016/j.drugalcdep.2013.01.013.
  16. Pennay A, Cameron J, Reichert T, et al. A systematic review of interventions for co-occurring substance use disorder and borderline personality disorder. J Subst Abuse Treat. 2011;41(4):363-373. doi:10.1016/j.jsat.2011.05.004.
  17. Lubman DI, King JA, Castle DJ. Treating comorbid substance use disorders in schizophrenia. Int Rev Psychiatry Abingdon Engl. 2010;22(2):191-201. doi:10.3109/09540261003689958.
  18. Substance Abuse and Mental Health Services Administration (SAHMSA). Mental and Substance Use Disorders. https://www.samhsa.gov/disorders. Published June 20, 2014. Accessed February 21, 2018.
  19. Katz C, El-Gabalawy R, Keyes KM, Martins SS, Sareen J. Risk factors for incident nonmedical prescription opioid use and abuse and dependence: results from a longitudinal nationally representative sample. Drug Alcohol Depend. 2013;132(1-2):107-113. doi:10.1016/j.drugalcdep.2013.01.010.
  20. Goldner EM, Lusted A, Roerecke M, Rehm J, Fischer B. Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: systematic review and meta-analyses. Addict Behav. 2014;39(3):520-531. doi:10.1016/j.addbeh.2013.11.022.
  21. Sheidow AJ, McCart M, Zajac K, Davis M. Prevalence and impact of substance use among emerging adults with serious mental health conditions. Psychiatr Rehabil J. 2012;35(3):235-243. doi:10.2975/35.3.2012.235.243.
  22. Bukstein OG, Horner MS. Management of the adolescent with substance use disorders and comorbid psychopathology. Child Adolesc Psychiatr Clin N Am. 2010;19(3):609-623. doi:10.1016/j.chc.2010.03.011.
  23. Sterling S, Weisner C, Hinman A, Parthasarathy S. Access to Treatment for Adolescents With Substance Use and Co-Occurring Disorders: Challenges and Opportunities. J Am Acad Child Adolesc Psychiatry. 2010;49(7):637-726. doi:10.1016/j.jaac.2010.03.019.
  24. Winters KC, Tanner-Smith EE, Bresani E, Meyers K. Current advances in the treatment of adolescent drug use. Adolesc Health Med Ther. 2014;5:199-210. doi:10.2147/AHMT.S48053.
  25. Barkus E, Murray RM. Substance use in adolescence and psychosis: clarifying the relationship. Annu Rev Clin Psychol. 2010;6:365-389. doi:10.1146/annurev.clinpsy.121208.131220.
  26. Parakh P, Basu D. Cannabis and psychosis: have we found the missing links? Asian J Psychiatry. 2013;6(4):281-287. doi:10.1016/j.ajp.2013.03.012.
  27. Pelayo-Terán JM, Suárez-Pinilla P, Chadi N, Crespo-Facorro B. Gene-environment interactions underlying the effect of cannabis in first episode psychosis. Curr Pharm Des. 2012;18(32):5024-5035.
  28. Goldstein BI, Bukstein OG. Comorbid substance use disorders among youth with bipolar disorder: opportunities for early identification and prevention. J Clin Psychiatry. 2010;71(3):348-358. doi:10.4088/JCP.09r05222gry.
  29. O’Neil KA, Conner BT, Kendall PC. Internalizing disorders and substance use disorders in youth: comorbidity, risk, temporal order, and implications for intervention. Clin Psychol Rev. 2011;31(1):104-112. doi:10.1016/j.cpr.2010.08.002.
  30. Wilens TE, Martelon M, Joshi G, et al. Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. J Am Acad Child Adolesc Psychiatry. 2011;50(6):543-553. doi:10.1016/j.jaac.2011.01.021.
  31. Zulauf CA, Sprich SE, Safren SA, Wilens TE. The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders. Curr Psychiatry Rep. 2014;16(3):436. doi:10.1007/s11920-013-0436-6.
  32. Nelson A, Galon P. Exploring the relationship among ADHD, stimulants, and substance abuse. J Child Adolesc Psychiatr Nurs Off Publ Assoc Child Adolesc Psychiatr Nurses Inc. 2012;25(3):113-118. doi:10.1111/j.1744-6171.2012.00322.x.
  33. Cerdá M, Sagdeo A, Johnson J, Galea S. Genetic and environmental influences on psychiatric comorbidity: a systematic review. J Affect Disord. 2010;126(1-2):14-38. doi:10.1016/j.jad.2009.11.006.
  34. Tsuang MT, Francis T, Minor K, Thomas A, Stone WS. Genetics of smoking and depression. Hum Genet. 2012;131(6):905-915. doi:10.1007/s00439-012-1170-6.
  35. Nestler EJ. Epigenetic mechanisms of drug addiction. Neuropharmacology. 2014;76 Pt B:259-268. doi:10.1016/j.neuropharm.2013.04.004.
  36. Fontenelle LF, Oostermeijer S, Harrison BJ, Pantelis C, Yücel M. Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments. Drugs. 2011;71(7):827-840. doi:10.2165/11591790-000000000-00000.
  37. Wang J-C, Kapoor M, Goate AM. The genetics of substance dependence. Annu Rev Genomics Hum Genet. 2012;13:241-261. doi:10.1146/annurev-genom-090711-163844.
  38. Enoch M-A. The influence of gene-environment interactions on the development of alcoholism and drug dependence. Curr Psychiatry Rep. 2012;14(2):150-158. doi:10.1007/s11920-011-0252-9.
  39. Hartz SM, Bierut LJ. Genetics of addictions. Psychiatr Clin North Am. 2010;33(1):107-124. doi:10.1016/j.psc.2009.10.003.
  40. Mahgoub M, Monteggia LM. Epigenetics and psychiatry. Neurother J Am Soc Exp Neurother. 2013;10(4):734-741. doi:10.1007/s13311-013-0213-6.
  41. Guintivano J, Kaminsky ZA. Role of epigenetic factors in the development of mental illness throughout life. Neurosci Res. 2016;102:56-66. doi:10.1016/j.neures.2014.08.003.
  42. Peña CJ, Bagot RC, Labonté B, Nestler EJ. Epigenetic signaling in psychiatric disorders. J Mol Biol. 2014;426(20):3389-3412. doi:10.1016/j.jmb.2014.03.016.
  43. Wing VC, Wass CE, Soh DW, George TP. A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann N Y Acad Sci. 2012;1248:89-106. doi:10.1111/j.1749-6632.2011.06261.x.
  44. Howes OD, Fusar-Poli P, Bloomfield M, Selvaraj S, McGuire P. From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments. Curr Pharm Des. 2012;18(4):459-465.
  45. Volkow ND, Fowler JS, Wang G-J, Swanson JM, Telang F. Dopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications. Arch Neurol. 2007;64(11):1575-1579. doi:10.1001/archneur.64.11.1575.
  46. Xing B, Li Y-C, Gao W-J. Norepinephrine versus Dopamine and their Interaction in Modulating Synaptic Function in the Prefrontal Cortex. Brain Res. 2016;1641(Pt B):217-233. doi:10.1016/j.brainres.2016.01.005.
  47. Marazziti D. Understanding the role of serotonin in psychiatric diseases. F1000Research. 2017;6. doi:10.12688/f1000research.10094.1.
  48. Müller CP, Homberg JR. The role of serotonin in drug use and addiction. Behav Brain Res. 2015;277:146-192. doi:10.1016/j.bbr.2014.04.007.
  49. Tsapakis EM, Travis MJ. Glutamate and psychiatric disorders. Adv Psychiatr Treat. 2002;8(3):189-197. doi:10.1192/apt.8.3.189.
  50. Tzschentke TM, Schmidt WJ. Glutamatergic mechanisms in addiction. Mol Psychiatry. 2003;8(4):373-382. doi:10.1038/sj.mp.4001269.
  51. Kumar K, Sharma S, Kumar P, Deshmukh R. Therapeutic potential of GABAB receptor ligands in drug addiction, anxiety, depression and other CNS disorders. Pharmacol Biochem Behav. 2013;110:174-184. doi:10.1016/j.pbb.2013.07.003.
  52. Aston-Jones G, Kalivas PW. Brain norepinephrine rediscovered in addiction research. Biol Psychiatry. 2008;63(11):1005-1006. doi:10.1016/j.biopsych.2008.03.016.
  53. Langer SZ. α2-Adrenoceptors in the treatment of major neuropsychiatric disorders. Trends Pharmacol Sci. 2015;36(4):196-202. doi:10.1016/j.tips.2015.02.006.
  54. Norman SB, Myers US, Wilkins KC, et al. Review of biological mechanisms and pharmacological treatments of comorbid PTSD and substance use disorder. Neuropharmacology. 2012;62(2):542-551. doi:10.1016/j.neuropharm.2011.04.032.
  55. Sinha R. Chronic Stress, Drug Use, and Vulnerability to Addiction. Ann N Y Acad Sci. 2008;1141:105-130. doi:10.1196/annals.1441.030.
  56. Brewer JA, Bowen S, Smith JT, Marlatt GA, Potenza MN. Mindfulness-Based Treatments for Co-Occurring Depression and Substance Use Disorders: What Can We Learn from the Brain? Addict Abingdon Engl. 2010;105(10):1698-1706. doi:10.1111/j.1360-0443.2009.02890.x.
  57. Berenz EC, Coffey SF. Treatment of Co-occurring Posttraumatic Stress Disorder and Substance Use Disorders. Curr Psychiatry Rep. 2012;14(5):469-477. doi:10.1007/s11920-012-0300-0.
  58. Boden MT, Kimerling R, Kulkarni M, Bonn-Miller MO, Weaver C, Trafton J. Coping among military veterans with PTSD in substance use disorder treatment. J Subst Abuse Treat. 2014;47(2):160-167. doi:10.1016/j.jsat.2014.03.006.
  59. Golub A, Vazan P, Bennett AS, Liberty HJ. Unmet need for treatment of substance use disorders and serious psychological distress among veterans: a nationwide analysis using the NSDUH. Mil Med. 2013;178(1):107-114.
  60. Wisco BE, Marx BP, Wolf EJ, Miller MW, Southwick SM, Pietrzak RH. Posttraumatic stress disorder in the US veteran population: results from the National Health and Resilience in Veterans Study. J Clin Psychiatry. 2014;75(12):1338-1346. doi:10.4088/JCP.14m09328.
  61. VA Health Care, National Center for PTSD. Understanding PTSD and Substance Abuse. National Center for Posttraumatic Stress Disorder; 2011. http://www.narbha.org/includes/media/docs/sudptsdflyer.pdf.
  62. Baigent M. Managing patients with dual diagnosis in psychiatric practice. Curr Opin Psychiatry. 2012;25(3):201-205. doi:10.1097/YCO.0b013e3283523d3d.
  63. Post RM, Kalivas P. Bipolar disorder and substance misuse: pathological and therapeutic implications of their comorbidity and cross-sensitisation. Br J Psychiatry J Ment Sci. 2013;202(3):172-176. doi:10.1192/bjp.bp.112.116855.
  64. Pérez de Los Cobos J, Siñol N, Puerta C, Cantillano V, López Zurita C, Trujols J. Features and prevalence of patients with probable adult attention deficit hyperactivity disorder who request treatment for cocaine use disorders. Psychiatry Res. 2011;185(1-2):205-210. doi:10.1016/j.psychres.2009.03.019.
  65. Berlin I, Hu M-C, Covey LS, Winhusen T. Attention-deficit/hyperactivity disorder (ADHD) symptoms, craving to smoke, and tobacco withdrawal symptoms in adult smokers with ADHD. Drug Alcohol Depend. 2012;124(3):268-273. doi:10.1016/j.drugalcdep.2012.01.019.
  66. Seitz A, Wapp M, Burren Y, Stutz S, Schläfli K, Moggi F. Association between craving and attention deficit/hyperactivity disorder symptoms among patients with alcohol use disorders. Am J Addict. 2013;22(3):292-296. doi:10.1111/j.1521-0391.2012.12000.x.
  67. Aubin H-J, Rollema H, Svensson TH, Winterer G. Smoking, quitting, and psychiatric disease: a review. Neurosci Biobehav Rev. 2012;36(1):271-284. doi:10.1016/j.neubiorev.2011.06.007.
  68. Minichino A, Bersani FS, Calò WK, et al. Smoking behaviour and mental health disorders--mutual influences and implications for therapy. Int J Environ Res Public Health. 2013;10(10):4790-4811. doi:10.3390/ijerph10104790.
  69. Center for Behavioral Health Statistics and Quality. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017.
  70. Winterer G. Why do patients with schizophrenia smoke? Curr Opin Psychiatry. 2010;23(2):112-119. doi:10.1097/YCO.0b013e3283366643.
  71. Donald S, Chartrand H, Bolton JM. The relationship between nicotine cessation and mental disorders in a nationally representative sample. J Psychiatr Res. 2013;47(11):1673-1679. doi:10.1016/j.jpsychires.2013.05.011.
  72. Mackowick KM, Lynch M-J, Weinberger AH, George TP. Treatment of tobacco dependence in people with mental health and addictive disorders. Curr Psychiatry Rep. 2012;14(5):478-485. doi:10.1007/s11920-012-0299-2.
  73. Moran LV, Sampath H, Kochunov P, Hong LE. Brain circuits that link schizophrenia to high risk of cigarette smoking. Schizophr Bull. 2013;39(6):1373-1381. doi:10.1093/schbul/sbs149.
  74. Murthy P, Chand P. Treatment of dual diagnosis disorders. Curr Opin Psychiatry. 2012;25(3):194-200. doi:10.1097/YCO.0b013e328351a3e0.
  75. Dineley KT, Pandya AA, Yakel JL. Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci. 2015;36(2):96-108. doi:10.1016/j.tips.2014.12.002.
  76. Ragg M, Gordon R, Ahmed T, Allan J. The impact of smoking cessation on schizophrenia and major depression. Australas Psychiatry Bull R Aust N Z Coll Psychiatr. 2013;21(3):238-245. doi:10.1177/1039856213486213.
  77. Tsoi DT, Porwal M, Webster AC. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. Br J Psychiatry J Ment Sci. 2010;196(5):346-353. doi:10.1192/bjp.bp.109.066019.
  78. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;(2):CD007253. doi:10.1002/14651858.CD007253.pub3.
  79. Cerimele JM, Durango A. Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies. J Clin Psychiatry. 2012;73(8):e1039-1047. doi:10.4088/JCP.11r07410.
  80. Morojele NK, Saban A, Seedat S. Clinical presentations and diagnostic issues in dual diagnosis disorders. Curr Opin Psychiatry. 2012;25(3):181-186. doi:10.1097/YCO.0b013e328351a429.
  81. Mueser KT, Gingerich S. Treatment of co-occurring psychotic and substance use disorders. Soc Work Public Health. 2013;28(3-4):424-439. doi:10.1080/19371918.2013.774676.
  82. Torrens M, Rossi PC, Martinez-Riera R, Martinez-Sanvisens D, Bulbena A. Psychiatric co-morbidity and substance use disorders: treatment in parallel systems or in one integrated system? Subst Use Misuse. 2012;47(8-9):1005-1014. doi:10.3109/10826084.2012.663296.
  83. Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav. 2012;37(1):11-24. doi:10.1016/j.addbeh.2011.09.010.
  84. DeMarce JM, Lash SJ, Stephens RS, Grambow SC, Burden JL. Promoting continuing care adherence among substance abusers with co-occurring psychiatric disorders following residential treatment. Addict Behav. 2008;33(9):1104-1112. doi:10.1016/j.addbeh.2008.02.008.
  85. Hunt GE, Siegfried N, Morley K, Sitharthan T, Cleary M. Psychosocial Interventions for People With Both Severe Mental Illness and Substance Misuse. Schizophr Bull. 2014;40(1):18-20. doi:10.1093/schbul/sbt160.
  86. Sacks S, Sacks J. Research on the effectiveness of the modified therapeutic community for persons with co-occurring substance use and mental disorders. Ther Communities. 2010;31:176-211.
  87. Lee SJ, Crowther E, Keating C, Kulkarni J. What is needed to deliver collaborative care to address comorbidity more effectively for adults with a severe mental illness? Aust N Z J Psychiatry. 2013;47(4):333-346. doi:10.1177/0004867412463975.
  88. Macgowan MJ, Engle B. Evidence for optimism: behavior therapies and motivational interviewing in adolescent substance abuse treatment. Child Adolesc Psychiatr Clin N Am. 2010;19(3):527-545. doi:10.1016/j.chc.2010.03.006.
  89. National Research Council (US) and Institute of Medicine (US) Committee on the Prevention of Mental Disorders and Substance Abuse Among Children, Youth, and Young Adults: Research Advances and Promising Interventions. Preventing Mental, Emotional, and Behavioral Disorders Among Young People: Progress and Possibilities. (O’Connell ME, Boat T, Warner KE, eds.). Washington (DC): National Academies Press (US); 2009. http://www.ncbi.nlm.nih.gov/books/NBK32775/. Accessed August 22, 2017..
  90. Szapocznik J, Zarate M, Duff J, Muir J. Brief strategic family therapy: engaging drug using/problem behavior adolescents and their families in treatment. Soc Work Public Health. 2013;28(3-4):206-223. doi:10.1080/19371918.2013.774666.
  91. Rowe CL. Multidimensional family therapy: addressing co-occurring substance abuse and other problems among adolescents with comprehensive family-based treatment. Child Adolesc Psychiatr Clin N Am. 2010;19(3):563-576. doi:10.1016/j.chc.2010.03.008.
  92. Axelrod SR, Perepletchikova F, Holtzman K, Sinha R. Emotion regulation and substance use frequency in women with substance dependence and borderline personality disorder receiving dialectical behavior therapy. Am J Drug Alcohol Abuse. 2011;37(1):37-42. doi:10.3109/00952990.2010.535582.
  93. Fries HP, Rosen MI. The efficacy of assertive community treatment to treat substance use. J Am Psychiatr Nurses Assoc. 2011;17(1):45-50. doi:10.1177/1078390310393509.
  94. Jainchill N, Hawke J, Messina M. Post-Treatment Outcomes Among Adjudicated Adolescent Males and Females in Modified Therapeutic Community Treatment. Subst Use Misuse. 2005;40(7):975-996. doi:10.1081/JA-200058857.
  95. Tidey JW. Using incentives to reduce substance use and other health risk behaviors among people with serious mental illness. Prev Med. 2012;55 Suppl:S54-60. doi:10.1016/j.ypmed.2011.11.010.
  96. Farren CK, Hill KP, Weiss RD. Bipolar disorder and alcohol use disorder: a review. Curr Psychiatry Rep. 2012;14(6):659-666. doi:10.1007/s11920-012-0320-9.
  97. Najavits LM, Hien D. Helping vulnerable populations: a comprehensive review of the treatment outcome literature on substance use disorder and PTSD. J Clin Psychol. 2013;69(5):433-479. doi:10.1002/jclp.21980.
  98. FDA permits marketing of mobile medical application for substance use disorder [FDA News Release]. Food and Drug Administration (FDA). https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576087.htm. Published September 14, 2017. Accessed February 8, 2018.
  99. Garland EL, Froeliger B, Zeidan F, Partin K, Howard MO. The Downward Spiral of Chronic Pain, Prescription Opioid Misuse, and Addiction: Cognitive, Affective, and Neuropsychopharmacologic Pathways. Neurosci Biobehav Rev. 2013;37(10 0 2):2597-2607. doi:10.1016/j.neubiorev.2013.08.006.
  100. Schulte MT, Hser Y-I. Substance Use and Associated Health Conditions throughout the Lifespan. Public Health Rev. 2014;35(2).
  101. Centers for Disease Control and Prevention (CDC). Data Brief 294. Drug Overdose Deaths in the United States, 1999–2016. National Center for Health Statistics https://www.cdc.gov/nchs/data/databriefs/db294_table.pdf#page=4.
  102. Berland D, Rodgers P. Rational use of opioids for management of chronic nonterminal pain. Am Fam Physician. 2012;86(3):252-258.
  103. Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012;15(3 Suppl):ES67-92.
  104. U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
  105. Kang H-J, Kim S-Y, Bae K-Y, et al. Comorbidity of Depression with Physical Disorders: Research and Clinical Implications. Chonnam Med J. 2015;51(1):8-18. doi:10.4068/cmj.2015.51.1.8.
  106. DeJean D, Giacomini M, Vanstone M, Brundisini F. Patient experiences of depression and anxiety with chronic disease: a systematic review and qualitative meta-synthesis. Ont Health Technol Assess Ser. 2013;13(16):1-33.
  107. Campbell ANC, Tross S, Caslyn DA. Substance Use Disorders and HIV/AIDS Prevention and Treatment Intervention: Research and Practice Considerations. Soc Work Public Health. 2013;28(0):333-348. doi:10.1080/19371918.2013.774665.
  108. Magura S, Rosenblum A, Fong C. Factors associated with medication adherence among psychiatric outpatients at substance abuse risk. Open Addict J. 2011;4:58-64. doi:10.2174/1874941001104010058.
  109. Bidell MR, McLaughlin M, Faragon J, Morse C, Patel N. Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. Infect Dis Ther. 2016;5(3):299-312. doi:10.1007/s40121-016-0118-x.
  110. El-Bassel N, Shaw SA, Dasgupta A, Strathdee SA. Drug use as a driver of HIV risks: re-emerging and emerging issues. Curr Opin HIV AIDS. 2014;9(2):150-155. doi:10.1097/COH.0000000000000035.
  111. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;55 Suppl 1:S3-9. doi:10.1093/cid/cis393.
  112. Young JQ, Kline-Simon AH, Mordecai DJ, Weisner C. Prevalence of behavioral health disorders and associated chronic disease burden in a commercially insured health system: findings of a case-control study. Gen Hosp Psychiatry. 2015;37(2):101-108. doi:10.1016/j.genhosppsych.2014.12.005.
  113. Shim RS, Koplan C, Langheim FJP, et al. Health care reform and integrated care: a golden opportunity for preventive psychiatry. Psychiatr Serv Wash DC. 2012;63(12):1231-1233. doi:10.1176/appi.ps.201200072.
  114. Centers for Disease Control and Prevention (CDC). HIV in the United States: At A Glance.; 2017. https://www.cdc.gov/hiv/statistics/overview/ataglance.html. Accessed February 8, 2018.
  115. Archin NM, Margolis DM. Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis. 2014;27(1):29-35. doi:10.1097/QCO.0000000000000026.
  116. Barton KM, Burch BD, Soriano-Sarabia N, Margolis DM. Prospects for treatment of latent HIV. Clin Pharmacol Ther. 2013;93(1):46-56. doi:10.1038/clpt.2012.202.
  117. Montaner JSG, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet Lond Engl. 2010;376(9740):532-539. doi:10.1016/S0140-6736(10)60936-1.
  118. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet Lond Engl. 2013;382(9904):1564-1574. doi:10.1016/S0140-6736(13)61530-5.
  119. Volkow ND, Baler RD, Normand JL. The unrealized potential of addiction science in curbing the HIV epidemic. Curr HIV Res. 2011;9(6):393-395.
  120. Centers for Disease Control and Prevention (CDC). HIV and Injection Drug Use.; 2017. https://www.cdc.gov/hiv/risk/idu.html. Accessed February 8, 2018.
  121. Dash S, Balasubramaniam M, Villalta F, Dash C, Pandhare J. Impact of cocaine abuse on HIV pathogenesis. Front Microbiol. 2015;6. doi:10.3389/fmicb.2015.01111.
  122. Hauser KF, Knapp PE. Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors. Int Rev Neurobiol. 2014;118:231-313. doi:10.1016/B978-0-12-801284-0.00009-9.
  123. Dahal S, Chitti SVP, Nair MPN, Saxena SK. Interactive effects of cocaine on HIV infection: implication in HIV-associated neurocognitive disorder and neuroAIDS. Front Microbiol. 2015;6:931. doi:10.3389/fmicb.2015.00931.
  124. Chang SL, Connaghan KP, Wei Y, Li MD. NeuroHIV and use of addictive substances. Int Rev Neurobiol. 2014;118:403-440. doi:10.1016/B978-0-12-801284-0.00013-0.
  125. Nasi M, Pinti M, De Biasi S, et al. Aging with HIV infection: a journey to the center of inflammAIDS, immunosenescence and neuroHIV. Immunol Lett. 2014;162(1 Pt B):329-333. doi:10.1016/j.imlet.2014.06.012.
  126. Alfahad TB, Nath A. Update on HIV-associated neurocognitive disorders. Curr Neurol Neurosci Rep. 2013;13(10):387. doi:10.1007/s11910-013-0387-7.
  127. Holt JL, Kraft-Terry SD, Chang L. Neuroimaging studies of the aging HIV-1-infected brain. J Neurovirol. 2012;18(4):291-302. doi:10.1007/s13365-012-0114-1.
  128. Laura M. Maruschak. HIV in Prisons, 2001-2010. U.S. Department of Justice; 2012. https://www.bjs.gov/content/pub/pdf/hivp10.pdf.
  129. Beckwith CG, Zaller ND, Fu JJ, Montague BT, Rich JD. Opportunities to diagnose, treat, and prevent HIV in the criminal justice system. J Acquir Immune Defic Syndr 1999. 2010;55 Suppl 1:S49-55. doi:10.1097/QAI.0b013e3181f9c0f7.
  130. Montague BT, Rosen DL, Solomon L, et al. Tracking linkage to HIV care for former prisoners. Virulence. 2012;3(3):319-324. doi:10.4161/viru.20432.
  131. Iroh PA, Mayo H, Nijhawan AE. The HIV Care Cascade Before, During, and After Incarceration: A Systematic Review and Data Synthesis. Am J Public Health. 2015;105(7):e5-16. doi:10.2105/AJPH.2015.302635.
  132. National Center for Health Statistics. Early Release of Selected Estimates Based on Data from The National Health Interview Survey. Atlanta, GA: Centers for Disease Control and Prevention; 2015. https://www.cdc.gov/nchs/data/nhis/earlyrelease/earlyrelease201506_10.pdf.
  133. Copen CE, Chandra A, Febo-Vazquez I. HIV Testing in the Past Year Among the U.S. Household Population Aged 15-44: 2011-2013. NCHS Data Brief. 2015;(202):1-8.
  134. Aletraris L, Roman PM. Provision of onsite HIV Services in Substance Use Disorder Treatment Programs: A Longitudinal Analysis. J Subst Abuse Treat. 2015;57:1-8. doi:10.1016/j.jsat.2015.04.005.
  135. The White House. National HIV/AIDS Strategy for the United States: Updated to 2020.; 2015. https://www.hiv.gov/federal-response/national-hiv-aids-strategy/overview.
  136. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.
  137. Friedman SR, Downing MJ, Smyrnov P, et al. Socially-integrated transdisciplinary HIV prevention. AIDS Behav. 2014;18(10):1821-1834. doi:10.1007/s10461-013-0643-5.
  138. Hull MW, Wu Z, Montaner JSG. Optimizing the engagement of care cascade: a critical step to maximize the impact of HIV treatment as prevention. Curr Opin HIV AIDS. 2012;7(6):579-586. doi:10.1097/COH.0b013e3283590617.
  139. Maina G, Mill J, Chaw-Kant J, Caine V. A systematic review of best practices in HIV care. J HIVAIDS Soc Serv. 2016;15(1):114-126.
  140. Montaner JSG. Treatment as prevention: toward an AIDS-free generation. Top Antivir Med. 2013;21(3):110-114.
  141. Castel AD, Magnus M, Greenberg AE. Pre-exposure prophylaxis for human immunodeficiency virus: the past, present, and future. Infect Dis Clin North Am. 2014;28(4):563-583. doi:10.1016/j.idc.2014.08.001.
  142. World Health Organization. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. World Health Organization; 2015. http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/.
  143. Baeten J, Grant R. Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know? Curr HIV/AIDS Rep. 2013;10(2):142-151. doi:10.1007/s11904-013-0157-9.
  144. Blumenthal J, Haubrich R. Pre-exposure Prophylaxis (PrEP) for HIV Infection: How Antiretroviral Pharmacology helps to Monitor and Improve Adherence. Expert Opin Pharmacother. 2013;14(13):1777-1785. doi:10.1517/14656566.2013.812072.
  145. Martin M, Vanichseni S, Suntharasamai P, et al. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. AIDS Lond Engl. 2015;29(7):819-824. doi:10.1097/QAD.0000000000000613.
  146. Escudero DJ, Lurie MN, Kerr T, Howe CJ, Marshall BDL. HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research. J Int AIDS Soc. 2014;17:18899.
  147. Burns DN, Grossman C, Turpin J, Elharrar V, Veronese F. Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies. Curr HIV/AIDS Rep. 2014;11(4):393-403. doi:10.1007/s11904-014-0234-8.
  148. Gwadz M, Cleland CM, Hagan H, et al. Strategies to uncover undiagnosed HIV infection among heterosexuals at high risk and link them to HIV care with high retention: a “seek, test, treat, and retain” study. BMC Public Health. 2015;15:481. doi:10.1186/s12889-015-1816-0.
  149. Meyer JP, Althoff AL, Altice FL. Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57(9):1309-1317. doi:10.1093/cid/cit427.
  150. Hood KB, Robertson AA, Baird-Thomas C. Implementing solutions to barriers to on-site HIV testing in substance abuse treatment: a tale of three facilities. Eval Program Plann. 2015;49:1-9. doi:10.1016/j.evalprogplan.2014.11.001.
  151. Hutchinson AB, Farnham PG, Sansom SL, Yaylali E, Mermin JH. Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States. J Acquir Immune Defic Syndr 1999. 2016;71(3):323-330. doi:10.1097/QAI.0000000000000838.
  152. Muga R, Langohr K, Tor J, et al. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs. Clin Infect Dis Off Publ Infect Dis Soc Am. 2007;45(3):370-376. doi:10.1086/519385.
  153. Lima VD, Nosyk B, Wood E, et al. Assessing the effectiveness of antiretroviral regimens in cohort studies involving Hiv-positive injection drug users. Aids. 2012;26(12):1491-1500. doi:10.1097/QAD.0b013e3283550b68.
  154. Centers for Disease Control and Prevention (CDC). More people with HIV have the virus under control [press release]. NCHHSTP Newsroom. https://www.cdc.gov/nchhstp/newsroom/2017/2017-HIV-Continuum-Press-Release.html. Published July 27, 2017. Accessed February 8, 2018.
  155. Bradley H, Hall HI, Wolitski RJ, et al. Vital Signs: HIV Diagnosis, Care, and Treatment Among Persons Living with HIV — United States, 2011. Centers for Disease Control and Prevention (CDC); 2014. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6347a5.htm#fig2. Accessed February 8, 2018.
  156. Durvasula R, Miller TR. Substance abuse treatment in persons with HIV/AIDS: challenges in managing triple diagnosis. Behav Med Wash DC. 2014;40(2):43-52. doi:10.1080/08964289.2013.866540.
  157. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;56(6):806-816. doi:10.1093/cid/cis1007.
  158. Carrico AW, Flentje A, Gruber VA, et al. Community-Based Harm Reduction Substance Abuse Treatment with Methamphetamine-Using Men Who Have Sex with Men. J Urban Health. 2014;91(3):555-567. doi:10.1007/s11524-014-9870-y.
  159. Joseph B, Wood E, Hayashi K, et al. Factors associated with initiation of antiretroviral therapy among HIV-positive people who use injection drugs in a Canadian setting. AIDS Lond Engl. 2016;30(6):925-932. doi:10.1097/QAD.0000000000000989.
  160. Buckingham E, Schrage E, Cournos F. Why the Treatment of Mental Disorders Is an Important Component of HIV Prevention among People Who Inject Drugs. Adv Prev Med. 2013;2013:690386. doi:10.1155/2013/690386.
  161. Kamarulzaman A, Altice FL. The Challenges in Managing HIV in People Who Use Drugs. Curr Opin Infect Dis. 2015;28(1):10-16. doi:10.1097/QCO.0000000000000125.
  162. McGovern MP, Lambert-Harris C, Gotham HJ, Claus RE, Xie H. Dual diagnosis capability in mental health and addiction treatment services: An assessment of programs across multiple state systems. Adm Policy Ment Health. 2014;41(2):205-214. doi:10.1007/s10488-012-0449-1.
  163. Croft B, Parish SL. Care Integration in the Patient Protection and Affordable Care Act: Implications for Behavioral Health. Adm Policy Ment Health. 2013;40(4). doi:10.1007/s10488-012-0405-0.
  164. Perfas FB, Spross S. Why the concept-based therapeutic community can no longer be called drug-free. J Psychoactive Drugs. 2007;39(1):69-79. doi:10.1080/02791072.2007.10399866.
  165. James DJ, Glaze LE. Mental Health Problems of Prison and Jail Inmates.; 2006.
  166. Baillargeon J, Penn JV, Knight K, Harzke AJ, Baillargeon G, Becker EA. Risk of reincarceration among prisoners with co-occurring severe mental illness and substance use disorders. Adm Policy Ment Health. 2010;37(4):367-374. doi:10.1007/s10488-009-0252-9.
  167. Pating DR, Miller MM, Goplerud E, Martin J, Ziedonis DM. New systems of care for substance use disorders: treatment, finance, and technology under health care reform. Psychiatr Clin North Am. 2012;35(2):327-356. doi:10.1016/j.psc.2012.03.004.
  168. Mechanic D. Seizing opportunities under the Affordable Care Act for transforming the mental and behavioral health system. Health Aff Proj Hope. 2012;31(2):376-382. doi:10.1377/hlthaff.2011.0623.
  169. Druss BG, Mauer BJ. Health care reform and care at the behavioral health—primary care interface. Psychiatr Serv Wash DC. 2010;61(11):1087-1092. doi:10.1176/ps.2010.61.11.1087.

This page was last updated February 2018

Get this Publication

Ordering Publications

Call 1-877-643-2644 or:
NIDA Drug Pubs
Cite this article

NIDA. (2018, February 27). Common Comorbidities with Substance Use Disorders. Retrieved from https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders

press ctrl+c to copy
NIDA Notes: The Latest in Drug Abuse Research

​Research Reports

This series of reports simplifies the science of research findings for the educated lay public, legislators, educational groups, and practitioners. The series reports on research findings of national interest.

Lesson Plan and Activity Finder